Therapeutics/Diagnostics News

WASHINGTON — In patients with active Crohn’s disease, guselkumab was superior to both placebo and standard-of-care ustekinumab after 48 weeks of treatment, according to late-breaking data from the phase 3 GALAXI program.

WASHINGTON — In this video, Mark Genovese, MD, discusses results of the VIVID-1 study, in which mirikizumab demonstrated noninferiority to ustekinumab for week 52 clinical remission among patients with moderate to severe Crohn’s disease.

WASHINGTON — Maintenance Skyrizi 180 mg and 360 mg was superior to placebo in achieving clinical remission among patients with moderately to severely active ulcerative colitis who responded to 12-week induction therapy, according to data.

WASHINGTON — Entyvio is “safe and effective” for maintaining sustained steroid-free remission at 1 year in children with inflammatory bowel disease, more so in those with ulcerative colitis vs. Crohn’s disease, according to a researcher.

WASHINGTON — Mebeverine was not superior to placebo for the treatment of pediatric irritable bowel syndrome and functional abdominal pain, although active drug labeling significantly improved treatment success, researchers reported.

WASHINGTON — Darvadstrocel demonstrated “no statistically significant or clinically meaningful” benefit vs. placebo for complex perianal fistulas and Crohn’s disease, according to ADMIRE-CD II trial data presented at Digestive Disease Week.

WASHINGTON — Nearly 60% of patients with acute severe ulcerative colitis responded to Xeljanz 10 mg twice daily by day 7, with one-third of patients in steroid-free remission by 6 months, according to interim analysis data presented here.

WASHINGTON — Researchers have determined that several noninvasive tests could help identify candidates for treatment with Rezdiffra, as well as predict response, in metabolic dysfunction-associated steatohepatitis.

WASHINGTON — Survodutide sustained improvement in liver fat content, liver enzymes and fibrosis biomarkers in patients with metabolic dysfunction-associated steatohepatitis at 28 weeks, according to a late-breaking abstract presented here.

WASHINGTON — Vonoprazan effectively relieved heartburn symptoms in patients with nonerosive reflux disease as early as day 1 of treatment, with results persisting after a 4-week placebo-controlled period through 20 weeks, according to data.